Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma

被引：0
|
作者：
S Lee
Y H Park
K H Kim
E Y Cho
Y C Ahn
K Kim
Y-M Shim
J S Ahn
K Park
Y-H Im
机构：
[1] Samsung Medical Center,Division of Hematology
[2] Sungkyunkwan University School of Medicine,Oncology, Department of Medicine
[3] Samsung Medical Center,Department of Pathology
[4] Sungkyunkwan University School of Medicine,Department of Radiation Oncology
[5] Samsung Medical Center,Department of Thoracic Surgery
[6] Sungkyunkwan University School of Medicine,undefined
[7] Samsung Medical Center,undefined
[8] Sungkyunkwan University School of Medicine,undefined
来源：
British Journal of Cancer | 2010年 / 103卷
关键词：
oesophageal cancer; capecitabine; cisplatin; thymidine synthase (TS); thymidine phosphorylase (TP); excesion repair cross-complementation group 1 (ERCC1);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：845 / 851
页数：6
相关论文
共 50 条
  • [21] Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy
    Lee, Hyun Woo
    Choi, Yong-Won
    Han, Jae Ho
    Kim, Jang Hee
    Jung, Jae Ho
    Jeong, Seong Hyun
    Kang, Seok Yun
    Choi, Jin-Hyuk
    Oh, Young Taek
    Park, Kwang Joo
    Hwang, Sung Chul
    Sheen, Seung Soo
    LUNG CANCER, 2009, 65 (03) : 377 - 382
  • [22] Peripheral Blood Markers Predictive of Progression-Free Survival in Advanced Esophageal Squamous Cell Carcinoma Patients Treated With PD-1 Inhibitors Plus Chemotherapy as First-Line Therapy
    Chen, Wei
    Li, Dapeng
    Bian, Xuyu
    Wu, Yan
    Xu, Mengdan
    Wu, Mengyao
    Tao, Min
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2022, 75 (01): : 207 - 218
  • [23] Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
    Lu, Shijie
    Lou, Yake
    Rong, Yi
    Huang, Zirui
    Lin, Xiaodan
    Chen, Junying
    Luo, Kongjia
    CLINICAL DRUG INVESTIGATION, 2023, 43 (08) : 643 - 652
  • [24] Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
    Shijie Lu
    Yake Lou
    Yi Rong
    Zirui Huang
    Xiaodan Lin
    Junying Chen
    Kongjia Luo
    Clinical Drug Investigation, 2023, 43 : 643 - 652
  • [25] Protein expression levels of excision repair cross-complementation group 1 and xeroderma pigmentosum D correlate with response to platinum-based chemotherapy in the patients with advanced epithelial ovarian cancer
    Lin, K.
    Ye, D.
    Xie, X.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2008, 18 (05) : 1007 - 1012
  • [26] A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma
    Wang, Hai-ying
    Yao, Zhi-hua
    Tang, Hong
    Zhao, Yan
    Jin, Shui-ling
    Zhou, Wen-ping
    Yao, Shu-na
    Yang, Shu-jun
    Liu, Yan-yan
    Luo, Su-xia
    ONCOTARGET, 2017, 8 (05) : 7540 - 7547
  • [27] Excision repair cross complementation group1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma
    Handra-Luca, Adriana
    Hernandez, Juana
    Mountzios, Giannis
    Taranchon, Estelle
    Lacau-St-Guily, Jean
    Soria, Jean-Charles
    Fouret, Pierre
    CLINICAL CANCER RESEARCH, 2007, 13 (13) : 3855 - 3859
  • [28] The prognostic value of excission repair cross-complementation group one enzyme expression in locally advanced cervical carcinoma patients treated with cisplatin-based treatment: a meta-analysis
    Zhu, Jiahao
    Ji, Shengjun
    Hu, Qunchao
    Chen, Qingqing
    Liu, Zhengcao
    Wu, Jinchang
    Gu, Ke
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (01) : 35 - 41
  • [29] Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
    Zhou, W
    Gurubhagavatula, S
    Liu, G
    Park, S
    Neuberg, DS
    Wain, JC
    Lynch, TJ
    Su, L
    Christiani, DC
    CLINICAL CANCER RESEARCH, 2004, 10 (15) : 4939 - 4943
  • [30] The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis
    Bisof, Vesna
    Petranovic, Matea Zajc
    Rakusic, Zoran
    Samardzic, Kristina Ruza
    Juretic, Antonio
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2016, 273 (09) : 2305 - 2317
12345